Researchers at National Taiwan University have developed a modular platform to reprogram tumor-derived extracellular vesicles (EVs), transforming them from oncogenic messengers into safe, customizable drug delivery vehicles through precise molecular editing.
Reprogramming the cancer messenger: A new era of tumor extracellular vesicle engineering
